{"Ticker": "RMD", "Company": "ResMed", "Sector": "Health Care", "Updated": "2022-08-12", "Rating": [{"Date": "2022-08-12", "Rating": "Downgrade", "Organization": "RBC Capital Mkts", "Rating_Change": "Outperform to Sector Perform", "Target_Change": "$246 to $252"}, {"Date": "2022-08-12", "Rating": "Downgrade", "Organization": "JP Morgan", "Rating_Change": "Overweight to Neutral", "Target_Change": ""}, {"Date": "2022-08-12", "Rating": "Downgrade", "Organization": "Citigroup", "Rating_Change": "Buy to Neutral", "Target_Change": ""}, {"Date": "2022-06-06", "Rating": "Upgrade", "Organization": "RBC Capital Mkts", "Rating_Change": "Sector Perform to Outperform", "Target_Change": "$233 to $244"}, {"Date": "2022-04-06", "Rating": "Initiated", "Organization": "Wolfe Research", "Rating_Change": "Outperform", "Target_Change": "$280"}, {"Date": "2022-01-31", "Rating": "Upgrade", "Organization": "Goldman", "Rating_Change": "Neutral to Buy", "Target_Change": ""}, {"Date": "2022-01-31", "Rating": "Upgrade", "Organization": "Citigroup", "Rating_Change": "Neutral to Buy", "Target_Change": ""}, {"Date": "2022-01-28", "Rating": "Upgrade", "Organization": "RBC Capital Mkts", "Rating_Change": "Underperform to Sector Perform", "Target_Change": "$234 to $241"}, {"Date": "2022-01-24", "Rating": "Upgrade", "Organization": "BofA Securities", "Rating_Change": "Underperform to Neutral", "Target_Change": "$239 to $250"}, {"Date": "2022-01-24", "Rating": "Upgrade", "Organization": "JP Morgan", "Rating_Change": "Neutral to Overweight", "Target_Change": ""}, {"Date": "2022-01-13", "Rating": "Upgrade", "Organization": "Robert W. Baird", "Rating_Change": "Neutral to Outperform", "Target_Change": "$270 to $300"}, {"Date": "2022-01-13", "Rating": "Upgrade", "Organization": "CLSA", "Rating_Change": "Outperform to Buy", "Target_Change": ""}, {"Date": "2021-12-21", "Rating": "Upgrade", "Organization": "KeyBanc Capital Markets", "Rating_Change": "Sector Weight to Overweight", "Target_Change": "$302"}, {"Date": "2021-12-06", "Rating": "Upgrade", "Organization": "Macquarie", "Rating_Change": "Neutral to Outperform", "Target_Change": ""}, {"Date": "2021-10-22", "Rating": "Upgrade", "Organization": "CLSA", "Rating_Change": "Underperform to Outperform", "Target_Change": ""}, {"Date": "2021-08-02", "Rating": "Downgrade", "Organization": "Needham", "Rating_Change": "Buy to Hold", "Target_Change": ""}, {"Date": "2021-08-02", "Rating": "Downgrade", "Organization": "CLSA", "Rating_Change": "Outperform to Sell", "Target_Change": ""}, {"Date": "2021-07-28", "Rating": "Upgrade", "Organization": "Jefferies", "Rating_Change": "Underperform to Hold", "Target_Change": "$170 to $240"}, {"Date": "2021-07-26", "Rating": "Downgrade", "Organization": "JP Morgan", "Rating_Change": "Overweight to Neutral", "Target_Change": "$245 to $246"}, {"Date": "2021-07-14", "Rating": "Initiated", "Organization": "RBC Capital Mkts", "Rating_Change": "Underperform", "Target_Change": "$223"}, {"Date": "2021-06-28", "Rating": "Downgrade", "Organization": "Citigroup", "Rating_Change": "Buy to Neutral", "Target_Change": ""}, {"Date": "2021-06-22", "Rating": "Upgrade", "Organization": "Macquarie", "Rating_Change": "Neutral to Outperform", "Target_Change": ""}, {"Date": "2021-06-22", "Rating": "Initiated", "Organization": "Robert W. Baird", "Rating_Change": "Neutral", "Target_Change": "$240"}, {"Date": "2021-06-21", "Rating": "Reiterated", "Organization": "Needham", "Rating_Change": "Buy", "Target_Change": "$229 to $267"}, {"Date": "2021-06-16", "Rating": "Downgrade", "Organization": "BofA Securities", "Rating_Change": "Neutral to Underperform", "Target_Change": "$216 to $221"}, {"Date": "2021-06-09", "Rating": "Upgrade", "Organization": "CLSA", "Rating_Change": "Sell to Outperform", "Target_Change": ""}, {"Date": "2021-05-21", "Rating": "Upgrade", "Organization": "JP Morgan", "Rating_Change": "Neutral to Overweight", "Target_Change": "$206 to $219"}, {"Date": "2021-05-11", "Rating": "Upgrade", "Organization": "Citigroup", "Rating_Change": "Neutral to Buy", "Target_Change": ""}, {"Date": "2021-04-30", "Rating": "Downgrade", "Organization": "Citigroup", "Rating_Change": "Buy to Neutral", "Target_Change": ""}, {"Date": "2021-03-16", "Rating": "Upgrade", "Organization": "Needham", "Rating_Change": "Hold to Buy", "Target_Change": "$229"}, {"Date": "2020-11-02", "Rating": "Upgrade", "Organization": "UBS", "Rating_Change": "Neutral to Buy", "Target_Change": "$210"}, {"Date": "2020-10-30", "Rating": "Upgrade", "Organization": "JP Morgan", "Rating_Change": "Underweight to Neutral", "Target_Change": "$165"}]}